Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of direct oral anticoagulants (dabigatran, rivaroxaban, or apixaban) versus warfarin in older ischemic stroke patients with atrial fibrillation: A real world study

Next Previous
Trial Profile

Efficacy of direct oral anticoagulants (dabigatran, rivaroxaban, or apixaban) versus warfarin in older ischemic stroke patients with atrial fibrillation: A real world study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 22 Jul 2019 Results assessing clinical effectiveness of DOACs (dabigartan, rivaroxaban, or apixaban) vs warfarin in patients with atrial fibrillation published in the JAMA Neurology
  • 13 Mar 2019 New trial record
  • 08 Feb 2019 Primary endpoint of home time has been met, according to results presented at the International Stroke Conference 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top